1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,701 | 0,751 | 16:54 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.09. | Aelis Farma: Availability of the 2026 Half-Year Financial Report | 396 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specialising in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| 15.09. | Aelis Farma Reports 2026 Half-Year Financial Results and Presents Progress and Development Outlook | 493 | Business Wire | The first half of 2026 was marked by: A positive opinion from the EMA Pediatric Committee on the Pediatric Investigation Plan for AEF0217, securing the development plan for this compound in... ► Artikel lesen | |
| AELIS FARMA Aktie jetzt für 0€ handeln | |||||
| 16.07. | Aelis Farma's Down syndrome trial clears safety review | 2 | Investing.com | ||
| 16.07. | Aelis Farma: Studie zu Down-Syndrom besteht Sicherheitsprüfung | 3 | Investing.com Deutsch | ||
| 16.07. | Aelis Farma Receives a Positive Recommendation From the Independent Data Monitoring Committee to Continue the Phase 2b Study of AEF0217 in People With Down Syndrome Without Modification | 879 | Business Wire | The Independent Data Monitoring Committee (IDMC) identified no safety concern and recommended that the current Phase 2b continue according to the current protocol. The findings further... ► Artikel lesen | |
| 22.06. | Aelis Farma announces share buyback program authorization | 5 | Investing.com | ||
| 22.06. | Aelis Farma: Availability of the Description of the Share Buyback Program | 382 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| 04.06. | Results of Aelis Farma Combined General Meeting of June 3, 2026 | 450 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| 13.05. | Aelis Farma: Combined General Meeting of June 3, 2026: Availability of Preparatory Documents and Participation and Voting Procedures | 617 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| 24.04. | Aelis Farma: Availability of the 2025 Universal Registration Document | 458 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving... ► Artikel lesen | |
| 07.04. | Aelis Farma Awarded a €458k Grant Under France 2030 in Nouvelle-Aquitaine to Support Development of Its Program in Obesity and Associated Metabolic Diseases | 451 | Business Wire | This non-dilutive funding, granted under the Projets d'Avenir Innovation (PAI) scheme, strengthens Aelis Farma's "metabolism" program and validates its innovation potential in a therapeutic area... ► Artikel lesen | |
| 30.03. | Aelis Farma Reports Its 2025 Annual Financial Results and Confirms Its 2026 Outlook | 797 | Business Wire | 2025 has been marked by several significant events: The achievement of key milestones for the Company's two drug candidates:
AEF0117: announcement of the final results of the Phase... ► Artikel lesen | |
| 21.03. | Aelis Farma announces the successful start of the recruitment of the Phase 2B clinical trial with AEF0217 for the treatment of behavioral and cognitive impairments of people with Down syndrome (Trisomy 21) | 944 | Business Wire | AEF0217 is a first-in-class Signalling Specific inhibitor of the CB1 receptor (CB1-SSi) developed as a treatment for impairments in adaptive behaviours and cognition in neurodevelopmental disorders... ► Artikel lesen | |
| 26.01. | Aelis Farma Announces Its 2026 Financial Calendar | 427 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral... ► Artikel lesen | |
| 12.01. | Aelis Farma Receives a Positive Opinion From EMA Pediatric Committee on the Pediatric Investigation Plan for AEF0217 in Down Syndrome | 502 | Business Wire | The EMA's Pediatric Committee (PDCO) has delivered a favorable consensus opinion on the Pediatric Investigational Plan (PIP) of Aelis Farma's first-in-class drug candidate AEF0217 for the treatment... ► Artikel lesen | |
| 02.12.25 | Aelis Farma Obtains Regulatory Approval of the Phase 2B Trial With AEF0217 in People With Down Syndrome | 606 | Business Wire | AEF0217 is a first-in-class CB1 receptor Signalling Specific inhibitor (CB1-SSi) developed as a potential first pharmacological treatment for impairments in adaptive behaviours and cognition... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,075 | +0,06 % | Neue Aufträge, neuer Aktionär, neues Gebot: Frische Fantasie bei HPQ Silicon, CTS Eventim und Qiagen | Erstellt und veröffentlicht im Auftrag von HPQ Silicon Manchmal genügt eine einzige Nachricht, um die Geschichte hinter einer Aktie neu zu schreiben. Bei HPQ Silicon sollen zertifizierte Hochleistungszellen... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 19,420 | 0,00 % | Mineralys Therapeutics, Inc. - 8-K, Current Report | ||
| TANGO THERAPEUTICS | 22,000 | -2,27 % | Tango Therapeutics (TNGX) vs. CRSP and SMMT: Can Vopimetostat Turn Promising Cancer Data Into an 89% Upside? | ||
| RECURSION PHARMACEUTICALS | 3,920 | -7,55 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| ABSCI | 10,920 | -9,75 % | Jefferies nimmt Absci mit "Buy" auf - Potenzial bei Wirkstoff gegen Haarausfall im Fokus | ||
| KINIKSA PHARMACEUTICALS | 92,97 | -4,70 % | Goldman Sachs raises Kiniksa stock price target on strong Arcalyst sales | ||
| COGENT BIOSCIENCES | 30,960 | -3,19 % | Stifel bekräftigt Kaufempfehlung für Cogent Biosciences nach ESMO-Daten | ||
| MODERNA | 199,14 | +0,66 % | 21 % Absturz: Daten-Leak löst Ausverkauf bei Moderna aus | © Foto: Jakub Porzycki - NurPhotoDie Moderna-Aktie bricht nach geleakten Studiendaten zu einem Krebsimpfstoff zweistellig ein. Dabei sind die Ergebnisse vielversprechend. Was steckt dahinter Enthaltene... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,910 | -1,79 % | Summit Therapeutics: Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China | First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 285,97 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| ERASCA | 14,280 | -4,67 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| NURIX THERAPEUTICS | 26,440 | -2,51 % | Nurix Therapeutics Swings To Profit In Q3 On Roche Licensing Revenue | SOUTH SAN FRANCISCO (dpa-AFX) - Nurix Therapeutics, Inc. (NRIX), clinical-stage biopharmaceutical company, reported a swing to profit in the third quarter from a loss in the year-ago period... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 118,41 | -3,38 % | Oppenheimer raises Kymera Therapeutics price target on drug data | ||
| STRYKER | 264,80 | +7,29 % | Ihre wichtigsten Termine: Spannende Zahlen von: Amazon, Starbucks, Mastercard, Eli Lilly und Caterpillar | © Foto: Dall-EGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte: FR0000120073,US0231351067... ► Artikel lesen | |
| EVOTEC | 2,838 | -3,14 % | Starke News und Kaufempfehlung: Vonovia, Evotec und Lahontan Gold Aktie | Starke News von Lahontan Gold. Der Explorer hat eine positive vorläufige Wirtschaftlichkeitsstudie (PEA) für sein Gold-Silber-Projekt Santa Fe im US-Bundesstaat Nevada veröffentlicht. Der Kapitalwert... ► Artikel lesen |
Das Unternehmen AELIS FARMA SAS kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,709 Euro und damit +10,26 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AELIS FARMA SAS finden Sie auf Wallstreet Online.